CN102028701B - Active ingredient composition for treating alcoholic liver injury - Google Patents
Active ingredient composition for treating alcoholic liver injury Download PDFInfo
- Publication number
- CN102028701B CN102028701B CN201010611136A CN201010611136A CN102028701B CN 102028701 B CN102028701 B CN 102028701B CN 201010611136 A CN201010611136 A CN 201010611136A CN 201010611136 A CN201010611136 A CN 201010611136A CN 102028701 B CN102028701 B CN 102028701B
- Authority
- CN
- China
- Prior art keywords
- active ingredient
- liver injury
- ingredient composition
- treating
- alcoholic liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an active ingredient composition for treating alcoholic liver injury, and relates to an active ingredient composition for treating liver injury. The invention solves the problems that the conventional traditional Chinese medicines and compound decoction thereof for treating liver injury are inconvenient to use, and the dosage and safety are difficult to control. The active ingredient composition for treating the alcoholic liver injury consists of 6, 7-dimethoxybenzopyran-2-one, geniposide and parietic acid. The active ingredient composition for treating the alcoholic liver injury has the advantages that: the clinical medicinal dosage is accurate, safe and effective, the active ingredient composition is convenient to use, the treatment effect is improved, medicinal materials are saved, and toxic and side effects are reduced; and the 6,7-dimethoxybenzopyran-2-one, the geniposide and the parietic acid have liver-protecting and gut-benefiting components having the advantages of quick absorption (short time to peak), slow metabolism (longer half life of medicines), higher peak concentration and larger blood concentration area under a curve, so the 6, 7-dimethoxybenzopyran-2-one, the geniposide and the parietic acid can serve as preferred active ingredients. The active ingredient composition provides a basis for subsequently preparing finished pharmaceutical products in various formulations.
Description
Technical field
The present invention relates to a kind of active ingredient composition of treating hepatic injury.
Background technology
The Chinese medicine and the compound recipe thereof of treatment hepatic injury are fried in shallow oil into decoction, though certain curative effect is arranged, in clinical practice, use inconveniently, and dosage, safety are difficult to control; This type medicament is taken not only time-consuming; Boil medicine and receive many condition restriction; Such as decocting time, decoct vessel, amount of water, the duration and degree of heating, be decocted first and the inferior method of boiling medicine in back is difficult to grasp, the person of boiling medicine fully by rule of thumb, subjective randomness is very strong; And short of reliable quality testing and monitoring means, many uncertain factors can't be guaranteed clinical efficacy; And Chinese patent medicine can't be added and subtracted with disease generally just to specific crowd, specific disease, and clinical application has significant limitation.Be difficult to monitoring owing to change in Chinese medicine and the compound recipe complicated component thereof, body.
Summary of the invention
The objective of the invention is to fry in shallow oil into decoction existence use inconvenience for the Chinese medicine and the compound recipe thereof that solve existing treatment hepatic injury, the unmanageable problem of dosage and safety, and a kind of active ingredient composition of treating alcoholic liver injury is provided.
The active ingredient composition of treatment alcoholic liver injury press ratio of quality and the number of copies by 16～20 parts 6,7-dimethoxy coumarin, 7～11 parts the chrysophanic acid composition of jasminoidin and 4～8 parts.
The present invention treats the active ingredient composition of alcoholic liver injury, and advantage is to guarantee that clinical medicine dose accurately with safe and effective, easy to use, improves curative effect, saves medical material, reduces toxic and side effects.
Characteristics of the present invention: the Chinese medicine and the compound recipe complicated component thereof of treatment hepatic injury; Action target spot is a lot, is difficult to the intravital warp-time variation of monitoring, 6; 7-dimethoxy coumarin, jasminoidin and chrysophanic acid have absorption fast (peak time is short); Metabolism slow (drug half-life is longer), it is higher to reach peak concentration, and the hepatic cholagogic composition that the blood drug level area is bigger under the curve can be used as first-selected active ingredient.
The active ingredient composition that the present invention treats alcoholic liver injury is that the finished product medicament of the various dosage forms of subsequent preparation provides the basis.
Description of drawings
Fig. 1 is the column spectrogram of Herba Artemisiae Scopariae Decoction lyophilized powder treatment index in the specific embodiment five, and wherein K2 is blank solvent, and M2 is the model solvent; YCHT is the Herba Artemisiae Scopariae Decoction lyophilized powder, 1 expression ALT, 2 expression AST; 3 expression ADH, 4 expression γ-GT, 5 expression TG; 6 expression GSH-Px, 7 expression MDA, 8 expression TP; Fig. 2 is the column spectrogram of the combination of active principles treatment index of treatment alcoholic liver injury in the specific embodiment five, and wherein K2 is blank solvent, and M2 is the model solvent; DGR is the combination of active principles of treatment alcoholic liver injury in the specific embodiment five, 1 expression ALT, 2 expression AST; 3 expression ADH, 4 expression γ-GT, 5 expression TG; 6 expression GSH-Px, 7 expression MDA, 8 expression TP.
The specific embodiment
Technical scheme of the present invention is not limited to the following cited specific embodiment, also comprises the combination in any between each specific embodiment.
The specific embodiment one: the combination of active principles of this embodiment treatment alcoholic liver injury press ratio of quality and the number of copies by 16～20 parts 6,7-dimethoxy coumarin, 7～11 parts jasminoidin and 4～8 parts chrysophanic acid composition.
The main performance index of the combination of active principles of treatment alcoholic liver injury in this embodiment:
1, alanine aminotransferase (ALT) index:
ALT mainly is distributed in the liver cytoplasm, if hepatic necrosis, alanine aminotransferase will raise, and the impaired degree of the degree of its rising and hepatocyte is consistent, therefore is one of at present the most frequently used liver function index.The ALT activity increases prompting hepatocyte destruction, permeability of cell membrane enhancing after giving ethanol.Prompting gives that rat normal physiological state is disturbed with ALT index correlation coefficient behind the ethanol, causes its coefficient rising.And make ALT index correlation coefficient produce reduction in various degree after giving respectively to organize relative medicine, point out each administration group that ethanol is caused hepatic injury and all have preventive effect to a certain degree.Produce farthest reduction with ALT index correlation coefficient behind the prescription in giving this embodiment, promptly the preventive effect of whole part group is best.Hence one can see that single become to divide into groups in 6, the 7-dimethoxy coumarin causes hepatic injury to ethanol and plays main therapeutical effect, is equipped with jasminoidin and can strengthens its effect, is equipped with chrysophanic acid again and can brings into play the merit that its assistant helps; Three medicine mutual reinforcements between are associated with, and the mutual-assistance is a usefulness, rise mutually each other to help the efficacy of a drug, and the merit that ethanol is caused treating liver injury significantly strengthens.
2, aspartate amino transferase (AST) index:
AST mainly is distributed in the hepatocyte, and the degree of its rising and the hepatocyte extent of damage are consistent, also is one of the most frequently used liver function index.Give that rat normal physiological state and AST index correlation coefficient are disturbed behind the ethanol, cause its coefficient to raise.Produced the trend that reduces in various degree and give each group of relative medicine with AST index phase relation number average, proved that each administration group causes hepatic injury to ethanol and all has preventive effect to a certain degree.Produce farthest reduction with AST index correlation coefficient behind the prescription in giving this embodiment, promptly the preventive effect of whole part group is best.
3, ethanol dehydrogenase (ADH) index:
ADH mainly is distributed in the hepatocyte; Ethanol main metabolic place in vivo, ethanol dehydrogenase are to make one of topmost enzyme of alcohol oxidation, and the ethanol of about 80-90% is through the ADH oxidation; The degree of its rising and the hepatocyte extent of damage are consistent, also are one of the most frequently used liver function indexs.Give that rat normal physiological state and ADH index correlation coefficient are disturbed behind the ethanol, cause its coefficient to raise.Produced the trend that reduces in various degree and give each group of relative medicine with ADH index phase relation number average, proved that each administration group causes hepatic injury to ethanol and all has preventive effect to a certain degree.Produce farthest reduction with ADH index correlation coefficient behind the prescription in giving this embodiment, promptly the preventive effect of whole part group is best.
4, gamma glutamyl transpeptidase (index of γ-GT):
γ-GT distributes very wide in vivo, but therefore γ-the GT in the serum has stronger specificity mainly from liver.γ-GT raises and has reflected the hepatocyte extent of damage and cholestasis.Give that rat normal physiological state and γ-GT index correlation coefficient are disturbed behind the ethanol, cause its coefficient to raise.Produced the trend that reduces in various degree and give each group of relative medicine with γ-GT index phase relation number average, proved that each administration group causes hepatic injury to ethanol and all has preventive effect to a certain degree.Produce farthest reduction with γ-GT index correlation coefficient behind the prescription in giving this embodiment, promptly the preventive effect of whole part group is best.
5, triglyceride (TG) index:
Give that rat normal physiological state and TG index correlation coefficient are disturbed behind the ethanol, cause its coefficient to raise.Produced the trend that reduces in various degree and give each group of relative medicine with TG index phase relation number average, proved that each administration group causes hepatic injury to ethanol and all has preventive effect to a certain degree.Produce farthest reduction with TG index correlation coefficient behind the prescription in giving this embodiment, promptly the preventive effect of whole part group is best.
6, malonaldehyde (MDA) index:
MDA is the end product of lipid peroxidation, and pair cell has direct damaging action, the degree that how much has reflected body inner lipid peroxide injury of its content.Liver function damaged after rat gave ethanol, and rat normal physiological state and MDA index correlation coefficient are disturbed, and caused its coefficient to raise.Produced the trend that reduces in various degree and give each group of relative medicine with MDA index phase relation number average, explained that each administration group causes hepatic injury to ethanol and all has preventive effect to a certain degree.Produce farthest rising with MDA index correlation coefficient behind the prescription in giving this embodiment, promptly the preventive effect of whole part group is best.
7, glutathion peroxidase (GSH-Px) index:
GSH-Px is that the endogenous or exogenous a kind of protective enzyme of the lipid peroxidation of generation of inducing of body antagonism is.GSH-Px avoids playing pivotal role in the radical damage process at the harmful peroxidating metabolite protection of removing cell.The vigor of glutathion peroxidase can take place obviously to raise or downward modulation under some pathological conditions.Give that rat normal physiological state and GSH-Px index correlation coefficient γ are disturbed behind the ethanol, cause its coefficient to reduce.Produced trend of rising in various degree and give each group of relative medicine with GSH-Px index phase relation number average, explained that each administration group causes hepatic injury to ethanol and all has preventive effect to a certain degree.Produce farthest rising with GSH-Px index correlation coefficient behind the prescription in giving this embodiment, promptly the preventive effect of whole part group is best.
8, total protein (TP) index:
TP is the index of reflection hepatocyte albumen anabolism function.Because total protein all is synthetic by liver, in case the liver complex functionality descends, above index decreases at blood middle concentration, and its reduction degree and the liver complex functionality extent of damage are proportionate.Give that rat normal physiological state and TP index correlation coefficient γ are disturbed behind the ethanol, cause its coefficient to raise.Produced the trend that reduces in various degree and give each group of relative medicine with TP index phase relation number average, explained that each administration group causes hepatic injury to ethanol and all has preventive effect to a certain degree.Produce farthest reduction with TP index correlation coefficient behind the prescription in giving this embodiment, promptly the preventive effect of whole part group is best.
The specific embodiment two: this embodiment and the specific embodiment one different be the treatment alcoholic liver injury combination of active principles by ratio of quality and the number of copies by 16 parts 6,7-dimethoxy coumarin, 7 parts jasminoidin and 4 parts chrysophanic acid are formed.Other is identical with the specific embodiment one.
The specific embodiment three: this embodiment and the specific embodiment one different be the treatment alcoholic liver injury combination of active principles by ratio of quality and the number of copies by 20 parts 6,7-dimethoxy coumarin, 11 parts jasminoidin and 8 parts chrysophanic acid are formed.Other is identical with the specific embodiment one.
The specific embodiment four: this embodiment and the specific embodiment one different be the treatment alcoholic liver injury combination of active principles by ratio of quality and the number of copies by 17～19 parts 6,7-dimethoxy coumarin, 8～10 parts jasminoidin and 5～7 parts chrysophanic acid are formed.Other is identical with the specific embodiment one.
The specific embodiment five: this embodiment and the specific embodiment one different be the treatment alcoholic liver injury combination of active principles by ratio of quality and the number of copies by 18 parts 6,7-dimethoxy coumarin, 9 parts jasminoidin and 6 parts chrysophanic acid are formed.Other is identical with the specific embodiment one.
The combination of active principles of treatment alcoholic liver injury in this embodiment; Effect (see figure 1) to ALT, AST, ADH, γ-GT, TG, MDA, GSH-Px and TP; Compare with Herba Artemisiae Scopariae Decoction lyophilized powder (YCHT) (see figure 2); Can know that the therapeutic effect of the combination of active principles of treatment alcoholic liver injury is identical with YCHT in this embodiment, all can play the effect of treatment alcoholic liver injury.
Claims (1)
1. active ingredient composition of treating alcoholic liver injury, the combination of active principles that it is characterized in that treating alcoholic liver injury by ratio of quality and the number of copies by 18 parts 6,7-dimethoxy coumarin, 9 parts jasminoidin and 6 parts chrysophanic acid are formed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010611136A CN102028701B (en) | 2010-12-29 | 2010-12-29 | Active ingredient composition for treating alcoholic liver injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010611136A CN102028701B (en) | 2010-12-29 | 2010-12-29 | Active ingredient composition for treating alcoholic liver injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102028701A CN102028701A (en) | 2011-04-27 |
| CN102028701B true CN102028701B (en) | 2012-09-19 |
Family
ID=43882511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010611136A Active CN102028701B (en) | 2010-12-29 | 2010-12-29 | Active ingredient composition for treating alcoholic liver injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102028701B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104688756A (en) * | 2013-12-09 | 2015-06-10 | 中国药科大学 | Pharmaceutical composition and its use in preparation of drug for treating alcoholic liver injury |
| CN103690553B (en) * | 2013-12-19 | 2016-03-23 | 上海市公共卫生临床中心 | A kind of pharmaceutical composition and application thereof of moving back hepatocellular jaundice |
| CN110354119A (en) * | 2018-03-26 | 2019-10-22 | 中国农业大学 | Application of the glycycoumarin in the drug of preparation prevention and/or medicine physical property hepatic injury |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101371882A (en) * | 2007-08-24 | 2009-02-25 | 曾雄辉 | Method for preparing Artemisia capillaris decoction formulation |
| CN101904839A (en) * | 2010-08-06 | 2010-12-08 | 中国人民解放军第二军医大学 | Application of imperatorin in preparing medicament for preventing and treating hepatitis or liver injury |
-
2010
- 2010-12-29 CN CN201010611136A patent/CN102028701B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101371882A (en) * | 2007-08-24 | 2009-02-25 | 曾雄辉 | Method for preparing Artemisia capillaris decoction formulation |
| CN101904839A (en) * | 2010-08-06 | 2010-12-08 | 中国人民解放军第二军医大学 | Application of imperatorin in preparing medicament for preventing and treating hepatitis or liver injury |
Non-Patent Citations (1)
| Title |
|---|
| 王喜军等.基于药物代谢组学的方剂配伍规律及配伍科学价值揭示.《中国中药杂志》.2010,第35卷(第10期),1346-1348. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102028701A (en) | 2011-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100382798C (en) | Pharmaceutical composition containing caffeoylquinic acids | |
| CN105582028A (en) | Use of antrodia camphorata for treating diseases | |
| CN105853877B (en) | Weight-losing pharmaceutical composition, preparation containing same and preparation method thereof | |
| WO2019024758A1 (en) | Application of glycoside compound in preparing drug for treating hepatic fibrosis | |
| CN102028701B (en) | Active ingredient composition for treating alcoholic liver injury | |
| Roh et al. | Herbal composition Gambigyeongsinhwan (4) from Curcuma longa, Alnus japonica, and Massa Medicata Fermentata inhibits lipid accumulation in 3T3-L1 cells and regulates obesity in Otsuka Long-Evans Tokushima Fatty rats | |
| CN104740425B (en) | A kind of pharmaceutical composition for treating rheumatic Bi syndrome and its production and use | |
| CN101057678B (en) | Composition containing natural plant extraction or monomer | |
| CN102357195B (en) | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof | |
| CN107106624A (en) | Prevention, the composition for the mixed extract containing mulberries and fuling peel for improving or treating degenerative neural disease | |
| CN103494866A (en) | Formulation method of formula for treating waist-leg ache | |
| CN102784237A (en) | Pharmaceutical composition for preventing or treating diabetic complications | |
| CN103610685A (en) | Traditional Chinese medicinal composition for treating dysmenorrhea | |
| CN102335362B (en) | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes | |
| CN101574411B (en) | Shuang dan orally disintegrating tablet | |
| Huang et al. | The modulative effects of microcurrent electrical nerve stimulation on diabetic mice | |
| HASIMUN et al. | Influences of Centella Asiatica and Curcuma Longa on Arterial Stiffness in a Hypertensive Animal Model | |
| CN108066334B (en) | Mechanism of lycium ruthenicum red pigment for resisting alcoholic liver injury and application of liver protection product of lycium ruthenicum red pigment | |
| CN101461802A (en) | Application of epi-gallocatechin-3-gallate in preparing medicament for preventing and treating high-fat fatty liver | |
| CN104740054A (en) | Pharmaceutical composition for treating myocardial ischemia as well as preparation method and use of pharmaceutical composition | |
| CN104258034A (en) | Traditional Chinese medicine composition for boosting immunity | |
| CN104256618A (en) | Food, health care product or medicine composition with blood sugar reduction function | |
| CN103877152B (en) | Compositionss containing granada seed oil and Oleum Perillae, Preparation Method And The Use | |
| KR20040080389A (en) | Fatigue recovery function by immune-enhancing effect and process for preparation thereof | |
| CN106266706B (en) | It is a kind of to treat Chinese medicine composition of diabetes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |